-+ 0.00%
-+ 0.00%
-+ 0.00%
Hutchmed (China)'s Blood Disorder Treatment Wins Simultaneous Approvals in China
Share
Listen to the news
06:13 AM EST, 11/19/2026 (MT Newswires) -- Hutchmed (China) (HCM.L) received simultaneous approval from China's National Medical Products Administration for two new drug applications of Syvik, a treatment for autoimmune blood disorders. The approval is for Syvik's treatment of adult patients with chronic primary immune thrombocytopenia, or ITP, who have had an insufficient response to at least one prior therapy, and warm antibody autoimmune hemolytic anemia, or wAIHA, who have had an insufficient response to prior corticosteroid therapy, according to a Thursday release. The decisions are supported by data from the phase 3 Eslim-01 trial in ITP and the phase 2/3 Eslim-02 trial in wAIHA, which showed significantly higher durable response rates with Syvik than with placebo.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending